{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T12:12:59Z","timestamp":1783944779727,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100017661","name":"China Health Promotion Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cgh.2026.05.010","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T07:00:39Z","timestamp":1779433239000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combined Upadacitinib and Vedolizumab as 8-Week Induction Therapy for Moderate-to-Severe Ulcerative Colitis: A Multicenter, Randomized Controlled Trial"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3410-7776","authenticated-orcid":false,"given":"Jiayin","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaocang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanfang","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huangwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lishuo","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengning","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8178-5572","authenticated-orcid":false,"given":"Min","family":"Zhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2026.05.010_bib1","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","article-title":"Ulcerative colitis","volume":"402","author":"Le Berre","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2026.05.010_bib2","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","article-title":"The global burden of IBD: from 2015 to 2025","volume":"12","author":"Kaplan","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.05.010_bib3","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2026.05.010_bib4","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2026.05.010_bib5","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.tips.2024.08.003","article-title":"Ulcerative colitis: clinical biomarkers, therapeutic targets, and emerging treatments","volume":"45","author":"Wangchuk","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.cgh.2026.05.010_bib6","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.cgh.2010.12.028","article-title":"Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis","volume":"9","author":"Ardizzone","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.05.010_bib7","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2026.05.010_bib8","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2026.05.010_bib9","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn's disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2026.05.010_bib10","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.14309\/ajg.0000000000002263","article-title":"Comparative speed of early symptomatic remission with advanced therapies for moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"118","author":"Ahuja","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2026.05.010_bib11","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2026.05.010_bib12","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","article-title":"JAK-STAT pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.05.010_bib13","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/j.cgh.2022.11.029","article-title":"Upadacitinib therapy reduces ulcerative colitis symptoms as early as day 1 of induction treatment","volume":"21","author":"Loftus","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.05.010_bib14","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","article-title":"Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"7","author":"Lasa","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.05.010_bib15","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1053\/j.gastro.2024.07.046","article-title":"Comparative efficacy of advanced therapies for management of moderate-to-severe ulcerative colitis: 2024 American Gastroenterological Association evidence synthesis","volume":"167","author":"Ananthakrishnan","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2026.05.010_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114174","article-title":"Breaking through the therapeutic ceiling of inflammatory bowel disease: dual-targeted therapies","volume":"158","author":"Feng","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.cgh.2026.05.010_bib17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","article-title":"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.05.010_bib18","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S2468-1253(23)00008-0","article-title":"Combination biologic therapy for ulcerative colitis","volume":"8","author":"Vermeire","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.05.010_bib19","doi-asserted-by":"crossref","first-page":"475","DOI":"10.5217\/ir.2024.00174","article-title":"Upadacitinib and vedolizumab combination therapy for the management of refractory ulcerative colitis and Crohn's disease","volume":"23","author":"Gilmore","year":"2025","journal-title":"Intest Res"},{"key":"10.1016\/j.cgh.2026.05.010_bib20","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1053\/j.gastro.2024.10.001","article-title":"AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis","volume":"167","author":"Singh","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2026.05.010_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cct.2005.08.003","article-title":"The use of unequal randomisation ratios in clinical trials: a review","volume":"27","author":"Dumville","year":"2006","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.cgh.2026.05.010_bib22","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1093\/ibd\/izad282","article-title":"Systematic literature review: ability of the IBDQ-32 to detect meaningful change in ulcerative colitis health indicators","volume":"30","author":"Dubinsky","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2026.05.010_bib23","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0016-5085(89)80080-0","article-title":"A new measure of health status for clinical trials in inflammatory bowel disease","volume":"96","author":"Guyatt","year":"1989","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2026.05.010_bib24","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2026.05.010_bib25","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3390\/biomedicines13010190","article-title":"An analysis of the effectiveness and safety of upadacitinib in the treatment of inflammatory bowel disease: a multicenter real-world study","volume":"13","author":"Wu","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.cgh.2026.05.010_bib26","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2026.05.010_bib27","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/ibd\/izae189","article-title":"Combined advanced targeted therapy in inflammatory bowel diseases: an extensive update","volume":"31","author":"Cornet","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2026.05.010_bib28","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3390\/jcm14020590","article-title":"Combining advanced targeted therapy in inflammatory bowel disease: current practice and future directions","volume":"14","author":"De Bernardi","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.cgh.2026.05.010_bib29","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.14309\/ajg.0000000000003463","article-title":"ACG clinical guideline update: ulcerative colitis in adults","volume":"120","author":"Rubin","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2026.05.010_bib30","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/ajg.2015.120","article-title":"C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis","volume":"110","author":"Mosli","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2026.05.010_bib31","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S2468-1253(25)00017-2","article-title":"Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study","volume":"10","author":"Panaccione","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.05.010_bib32","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1016\/j.cgh.2025.05.019","article-title":"Appropriate use and complications of corticosteroids in inflammatory bowel disease: a comprehensive review","volume":"23","author":"Feuerstein","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.05.010_bib33","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/ecco-jcc\/jjad190","article-title":"Impact of baseline corticosteroid use on the efficacy and safety of upadacitinib in patients with ulcerative colitis: a post hoc analysis of the Phase 3 clinical trial programme","volume":"18","author":"Raine","year":"2024","journal-title":"J Crohns Colitis"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356526003885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356526003885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:50:10Z","timestamp":1783943410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356526003885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":33,"alternative-id":["S1542356526003885"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2026.05.010","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined Upadacitinib and Vedolizumab as 8-Week Induction Therapy for Moderate-to-Severe Ulcerative Colitis: A Multicenter, Randomized Controlled Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2026.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Gastroenterological Association Institute. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}